FDA approves Dupixent for allergic fungal rhinosinusitis
Medical Xpress
February 26, 2026
The U.S. Food and Drug Administration has approved Dupixent (dupilumab) for the treatment of adult and pediatric patients aged 6 years and older with allergic fungal rhinosinusitis (AFRS) and a history of sino-nasal surgery.
Verticals
healthmedical
Originally published on Medical Xpress on 2/26/2026